Oncology was Johnson & Johnson’s largest segment in fiscal 2025, bringing in $25.38B of $94.19B (27%).
| Subsegments | FY 2022 | FY 2023 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Oncology | $14.55B | $15.98B | $17.66B | $20.78B | $25.38B |
| Immunology | $16.75B | $16.94B | $18.05B | $17.83B | $15.73B |
| Surgery | $9.81B | $9.69B | $10.04B | $9.85B | $10.14B |
| Orthopaedics | $8.59B | $8.59B | $8.94B | $9.16B | $9.26B |
| Neuroscience | $6.99B | $6.89B | $7.14B | $7.12B | $7.84B |
| Cardiovascular | — | $4.30B | $6.35B | $7.71B | $8.93B |
| Vision | $4.69B | $4.85B | $5.07B | $5.15B | $5.47B |
| Infectious Diseases | $5.83B | $5.45B | $4.42B | $3.40B | $3.24B |
| Interventional Solutions | $3.97B | — | — | — | — |
| Pulmonary Hypertension | $3.45B | $3.42B | $3.82B | $4.28B | $4.44B |
| Cardiovascular/Metabolism/Other | $4.12B | $3.89B | $3.67B | $3.56B | $3.78B |
| Total | $78.74B | $79.99B | $85.16B | $88.82B | $94.19B |
Johnson & Johnson brought in $94.19B from its 10 segments in fiscal 2025, the year ended December 28, 2025. That was up 6.0% from $88.82B in fiscal 2024. Oncology was the largest at $25.38B (26.9%), ahead of Immunology at $15.73B (16.7%) and Surgery at $10.14B (10.8%). The other seven segments brought in $42.95B combined.
Compared with fiscal 2024, Oncology grew fastest, up 22.1% to $25.38B, while Immunology fell the most, down 11.8% to $15.73B.
Johnson & Johnson began breaking out Cardiovascular in fiscal 2023, when it brought in $4.30B. Johnson & Johnson stopped reporting Interventional Solutions as a separate segment after fiscal 2022, when it brought in $3.97B.
United States was Johnson & Johnson’s largest region in fiscal 2025, bringing in $53.75B of $94.19B (57%).
| Geography | FY 2010 | FY 2011 | FY 2012 | FY 2012 | FY 2013 | FY 2014 | FY 2016 | FY 2017 | FY 2017 | FY 2018 | FY 2019 | FY 2021 | FY 2022 | FY 2023 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $40.64B | $41.98B | $46.44B | $50.30B | $53.75B | ||||||||||||
| U S | — | — | — | — | — | ||||||||||||
| Europe | $20.60B | $20.66B | $20.41B | $20.21B | $21.54B | ||||||||||||
| Asia-Pacific, Africa | $13.58B | $13.24B | $13.76B | $13.59B | $14.03B | ||||||||||||
| Segment, Geographical, Groups Of Countries, Group Two | — | — | — | — | — | ||||||||||||
| Segment Geographical Groups Of Countries Group Two | — | — | — | — | — | ||||||||||||
| Western Hemisphere Excluding U.S | $3.93B | $4.11B | $4.55B | $4.71B | $4.88B | ||||||||||||
| Western Hemisphere, Excluding U.S | — | — | — | — | — | ||||||||||||
| Segment, Geographical, Groups Of Countries, Group One | — | — | — | — | — | ||||||||||||
| Segment Geographical Groups Of Countries Group | — | — | — | — | — | ||||||||||||
| Total | $78.74B | $79.99B | $85.16B | $88.82B | $94.19B |
Johnson & Johnson brought in $94.19B from its four regions in fiscal 2025, the year ended December 28, 2025. That was up 6.0% from $88.82B in fiscal 2024. United States was the largest at $53.75B (57.1%), ahead of Europe at $21.54B (22.9%) and Asia-Pacific, Africa at $14.03B (14.9%). The remaining region, Western Hemisphere Excluding U.S, brought in $4.88B.
Compared with fiscal 2024, United States grew fastest, up 6.9% to $53.75B. Every region above 2% of revenue grew. From fiscal 2022 to 2025, combined revenue from these regions grew from $78.74B to $94.19B, a compound annual growth rate of 6.2%. United States' share of the total rose from 51.6% to 57.1%.
Innovative Medicine was Johnson & Johnson’s largest segment in fiscal 2025, bringing in $60.40B of $94.19B (64%).
| Segment | FY 2017 | FY 2017 | FY 2018 | FY 2019 | FY 2021 | FY 2022 | FY 2023 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Innovative Medicine | $51.68B | $52.56B | $54.76B | $56.96B | $60.40B | |||||
| Pharmaceutical | — | — | — | — | — | |||||
| Medtech | $27.06B | $27.43B | $30.40B | $31.86B | $33.79B | |||||
| Medical Devices | — | — | — | — | — | |||||
| Consumer Health | — | — | — | — | — | |||||
| Consumer | — | — | — | — | — | |||||
| Total | $78.74B | $79.99B | $85.16B | $88.82B | $94.19B |
Johnson & Johnson brought in $94.19B from its two segments in fiscal 2025, the year ended December 28, 2025. That was up 6.0% from $88.82B in fiscal 2024. Innovative Medicine was the largest at $60.40B (64.1%), ahead of Medtech at $33.79B (35.9%).
Compared with fiscal 2024, Medtech grew 6.1% to $33.79B and Innovative Medicine grew 6.0% to $60.40B. From fiscal 2022 to 2025, combined revenue from these segments grew from $78.74B to $94.19B, a compound annual growth rate of 6.2%. Innovative Medicine's share of the total fell from 65.6% to 64.1%.
Johnson & Johnson (JNJ) reports its revenue by subsegments, by geography and by segment. In fiscal 2025, Oncology was its largest segment, bringing in $25.38B (26.9% of the total), followed by Immunology at $15.73B (16.7%).
Oncology was Johnson & Johnson's largest segment in fiscal 2025, bringing in $25.38B, or 26.9% of the $94.19B total across its 10 segments.
United States was Johnson & Johnson's largest region in fiscal 2025, bringing in $53.75B, or 57.1% of the $94.19B total across its four regions.
Among Johnson & Johnson's segments that make up at least 2% of revenue, Oncology grew fastest in fiscal 2025, up 22.1% from $20.78B to $25.38B.
Every figure comes from Johnson & Johnson's annual financial filings, as reported. Each line keeps the name Johnson & Johnson gives it, and years follow its fiscal calendar.
Johnson & Johnson's revenue by subsegments goes back to fiscal 2022, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.